Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study.

Neurotherapeutics · 2021 · PMC8423885 · PMID 33844155

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

showed a trendp = 0.053so close (0.05 < p ≤ 0.1)

The estimated means for ARR showed a trend of significativity among the 3 groups, with value of 0.001 for patients on OCR, 0.308 for patients on RTX, and 0.500 for patients on CLA ( p = 0.053).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.